Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial
- 3 December 2004
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (7) , 842-848
- https://doi.org/10.1007/s00198-004-1770-7
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?Bone, 2000
- Monitoring Osteoporosis Therapy With Bone DensitometryMisleading Changes and Regression to the MeanJAMA, 2000
- Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosisArthritis & Rheumatism, 1999
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Report assessing vertebral fracturesJournal of Bone and Mineral Research, 1995
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993
- Design of the Fracture Intervention TrialOsteoporosis International, 1993
- Architecture and vertebral fractureCalcified Tissue International, 1993
- Vertebral structure and strengthIn vivo andIn vitroCalcified Tissue International, 1993
- Trabecular bone architecture in the pathogenesis and prevention of fractureThe American Journal of Medicine, 1987